Bright Minds Biosciences ... (DRUG)
NASDAQ: DRUG
· Real-Time Price · USD
30.21
-0.49 (-1.60%)
At close: May 01, 2025, 3:59 PM
30.99
2.58%
After-hours: May 01, 2025, 04:43 PM EDT
-1.60% (1D)
| Bid | 29.58 |
| Market Cap | 212.8M |
| Revenue (ttm) | n/a |
| Net Income (ttm) | -1.06M |
| EPS (ttm) | -0.15 |
| PE Ratio (ttm) | -201.4 |
| Forward PE | -10.15 |
| Analyst | Buy |
| Ask | 33 |
| Volume | 15,249 |
| Avg. Volume (20D) | 43,640 |
| Open | 31.13 |
| Previous Close | 30.70 |
| Day's Range | 30.11 - 31.49 |
| 52-Week Range | 0.93 - 79.02 |
| Beta | 1.02 |
About DRUG
Bright Minds Biosciences Inc., a pre-clinical biosciences company, develops 5-HT (serotonin) medicines to improve the lives of patients with severe and life-altering diseases. Its portfolio of selective 5-HT receptor agonists comprises 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry. The company has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Bra...
Industry Biotechnology
Sector Healthcare
IPO Date Mar 22, 2021
Employees NaN
Stock Exchange NASDAQ
Ticker Symbol DRUG
Website https://brightmindsbio.com
Analyst Forecast
According to 4 analyst ratings, the average rating for DRUG stock is "Buy." The 12-month stock price forecast is $85, which is an increase of 181.36% from the latest price.
Stock Forecasts5 months ago
-1.24%
Bright Minds Biosciences shares are trading higher...
Unlock content with
Pro Subscription
6 months ago
+1.72%
Bright Minds Biosciences shares are trading higher after the company announced a collaboration with Firefly Neuroscience to provide a full analysis of the EEG data in the BREAKTHROUGH study.
